Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / April 12, 2024 / RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and BioVie, Inc. (NASDAQ:BIVI) on the RedChip Small Stocks, Big Money show, a sponsored program on Bloomberg TV, this Saturday, April 13, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
佛羅里達州奧蘭多/ACCESSWIRE/2024年4月12日/RedChip Companies將在RedChip上播出對遺傳技術有限公司（納斯達克股票代碼：GENE）和BioVie, Inc.（納斯達克股票代碼：BIVI）的採訪 小股票，大資金 該節目是彭博電視臺贊助的節目，將於美國東部時間4月13日星期六晚上7點（美國東部時間）。據估計，彭博電視在美國有7,300萬個家庭可以觀看。
Access the interviews in their entirety at:
訪問訪談的全部內容，請訪問：
Genetic Technologies:
遺傳技術：
BioVie:
BioVie：
In an exclusive interview, Simon Morriss, CEO of Genetic Technologies, appears on the RedChip Small Stocks, Big Money Show on Bloomberg TV to provide a corporate update. Genetic Technologies is executing a B2B commercialization strategy for its flagship geneType multi-risk test covering breast cancer, colorectal cancer, prostate cancer, ovarian cancer, coronary artery disease and Type-2 diabetes, a first-in-class test that can predict a person's risk in up to 70% of annual mortalities and morbidities before onset. The Multi-Risk test, along with integration of recently acquired DNA based products, underpin a broad and complementary portfolio of genomic based tests creating a significant competitive advantage. GENE's expanding product portfolio includes more than 50 risk assessment tests in 14 test categories covered by 25 patents granted and nine patents pending. In addition to its B2B model, GENE is also focused on expanding its direct-to-consumer testing programs. The global market for predictive genomics is expected to reach $4.6 billion by 2025, growing at a CAGR of 17%+.
基因技術首席執行官西蒙·莫里斯在接受獨家採訪時出現在RedChip上 小股票，大資金 在彭博電視上播出以提供公司最新情況。Genetic Technologies正在爲其旗艦GeneType多風險測試執行B2B商業化戰略，該測試涵蓋乳腺癌、結直腸癌、前列腺癌、卵巢癌、冠狀動脈疾病和2型糖尿病，這是一項同類首創的測試，可以在發病前預測一個人在高達70％的死亡率和發病率中的風險。多風險測試以及最近收購的基於DNA的產品的整合，爲基因組測試的廣泛而互補的產品組合奠定了基礎，從而創造了顯著的競爭優勢。GENE不斷擴大的產品組合包括14個測試類別的50多項風險評估測試，涵蓋25項已授予的專利和9項正在申請的專利。除了其B2B模式外，GENE還專注於擴大其直接面向消費者的測試計劃。到2025年，預測基因組學的全球市場預計將達到46億美元，複合年增長率爲17％以上。
Cuong Do, President and CEO of BioVie, appears on the RedChip Small Stocks, Big Money Show on Bloomberg TV to provide a corporate update. BioVie is a clinical-stage company developing what it believes will be transformative therapies to overcome unmet medical needs in neurodegeneration and liver disease. The Company is developing NE3107 for Alzheimer's (AD) and Parkinson's (PD) and BIV201 for refractory ascites and HRS-AKI. BioVio recently reported data from a Phase 3 trial in AD that showed positive trending data showing that patients treated with NE3107 had treatment advantages compared to placebo on various cognitive, functional, and biomarker endpoints. The Company plans to launch Phase 3 trials in Alzheimer's, Parkinson's, and Ascites in 2024 and has multiple other efforts underway that may create additional catalysts.
BioVie總裁兼首席執行官Cuong Do出現在RedChip上 小股票，大資金 在彭博電視上播出以提供公司最新情況。BioVie是一家處於臨床階段的公司，正在開發其認爲將是變革性的療法，以克服神經變性和肝臟疾病中未得到滿足的醫療需求。該公司正在開發用於阿爾茨海默氏症（AD）和帕金森氏症（PD）的 NE3107 以及用於難治性腹水和 HRS-AKI 的 BIV201。BioVio 最近報告了一項 AD 三期試驗的數據，該數據顯示了積極的趨勢數據，表明與安慰劑相比，接受 NE3107 治療的患者在各種認知、功能和生物標誌物終點上具有治療優勢。該公司計劃在2024年啓動針對阿爾茨海默氏症、帕金森氏症和腹水的3期試驗，並正在進行其他多項可能創造更多催化劑的努力。
About Genetic Technologies
關於基因技術
Genetic Technologies Limited (ASX:GTG)(Nasdaq:GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness, and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit .
基因技術有限公司（澳大利亞證券交易所股票代碼：GTG）（納斯達克股票代碼：GENE）是一家多元化的分子診斷公司。通過其GeneType和EasyDNA品牌，成爲健康、保健和嚴重疾病基因組學測試領域的全球領導者。GTG提供癌症預測測試和評估工具，幫助醫生改善世界各地人們的健康狀況。該公司擁有專有的風險分層平台，該平台是在過去十年中開發的，該平台整合了臨床和遺傳風險，爲醫生和個人提供可操作的結果。基因技術在腫瘤、心血管和代謝疾病的風險預測方面處於世界領先地位，繼續開發風險評估產品。欲了解更多信息，請訪問。
About BioVie
關於 BioVie
BioVie Inc. (Nasdaq: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate NE3107 inhibits inflammatory activation of ERK and NFkB (e.g., TNF signaling) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both are drivers of Alzheimer's and Parkinson's diseases. The Company conducted and reported efficacy data from its randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease (NCT04669028). Results of a Phase 2 investigator-initiated trial (NCT05227820) showing NE3107-treated patients experienced improved cognition and biomarker levels were presented at the Clinical Trial in Alzheimer's Disease (CTAD) annual conference in December 2022. An estimated six million Americans suffer from Alzheimer's. A Phase 2 study of NE3107 in Parkinson's disease (NCT05083260) has completed, and data presented at the International Conference on Alzheimer's and Parkinson's Disease and Related Neurological Disorders conference in Gothenburg, Sweden in March 2023 showed significant improvements in "morning on" symptoms and clinically meaningful improvement in motor control in patients treated with a combination of NE3107 and levodopa vs. patients treated with levodopa alone, and no drug-related adverse events. In liver disease, the Company's Orphan drug candidate BIV201 (continuous infusion terlipressin), with U.S. FDA Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the treatment of ascites due to chronic liver cirrhosis. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit
BioVie Inc.（納斯達克股票代碼：BIVI）是一家臨床階段的公司，開發用於治療神經系統和神經退行性疾病以及晚期肝病的創新藥物療法。在神經退行性疾病中，該公司的候選藥物 NE3107 可抑制導致神經炎症和胰島素抵抗的 ERK 和 NFkB（例如腫瘤壞死因子信號）的炎症激活，但不抑制其穩態功能（例如胰島素信號傳導和神經元生長和存活）。兩者都是阿爾茨海默氏症和帕金森氏病的驅動因素。該公司進行並報告了其隨機、雙盲、安慰劑對照、平行組、多中心研究的療效數據，該研究旨在評估輕度至中度阿爾茨海默病（NCT04669028）患者的 NE3107。2022年12月的阿爾茨海默氏病臨床試驗（CTAD）年會上公佈了一項由研究者發起的2期試驗（NCT05227820）的結果，該試驗顯示接受NE3107治療的患者的認知和生物標誌物水平得到改善。估計有600萬美國人患有阿爾茨海默氏症。NE3107 在帕金森氏病（NCT05083260）中的2期研究已經完成，2023年3月在瑞典哥德堡舉行的阿爾茨海默氏症和帕金森氏病及相關神經系統疾病國際會議上公佈的數據顯示，與單獨使用左旋多巴的患者相比，使用 NE3107 和左旋多巴聯合治療的患者的 “早起” 症狀顯著改善，運動控制具有臨床意義的改善，沒有與藥物相關的不良事件。在肝臟疾病方面，正在評估和討論該公司具有美國食品藥品管理局快速通道地位的孤兒候選藥物 BIV201（持續輸注特利加壓素），並獲得美國食品藥品管理局關於治療慢性肝硬化引起的腹水的 BIV201 的三期臨床試驗的設計指導。該活性劑已在美國和約40個國家獲准用於晚期肝硬化的相關併發症。欲了解更多信息，請訪問
About RedChip Companies
關於紅籌公司
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 32 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
RedChip Companies是一家5000公司，是一家國際投資者關係、媒體和研究公司，專注於微型股和小盤股公司。32年來，RedChip爲其客戶提供了具體、可衡量的業績。我們的時事通訊， 小股票，大資金， 每週向60,000名投資者在線交付。RedChip爲微型股和小盤股公司開發了業內最全面的服務平台。這些服務包括：股票研究的全球分銷網絡；美國主要城市的零售和機構路演；向股票經紀商、RIA、機構和家族辦公室進行境外營銷；產生數百萬獨特投資者觀點的數字媒體投資者關係平台；投資者網絡研討會和群組電話；電視節目， 小股票，大資金，每週在美國彭博社播出；本地和全國市場的電視廣告；企業和產品視頻；網站設計；以及傳統的投資者關係服務，包括新聞稿撰寫、投資者演示文稿的編寫、季度電話會議腳本撰寫、戰略諮詢、籌集資金等。
To learn more about RedChip's products and services, please visit:
要了解有關RedChip產品和服務的更多信息，請訪問：
"Discovering Tomorrow's Blue Chips Today"
“今天發現明天的藍籌股”
Follow RedChip on LinkedIn:
在領英上關注 RedChip：
Follow RedChip on Facebook:
在臉書上關注 RedChip：
Follow RedChip on Instagram:
在 Instagram 上關注 RedChip
Follow RedChip on Twitter:
在推特上關注 RedChip：
Follow RedChip on YouTube:
在 YouTube 上關注 RedChip
Follow RedChip on Rumble:
在 Rumble 上關注 RedChip：
Subscribe to our Mailing List:
訂閱我們的郵件列表：
Contact:
聯繫人：
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com
戴夫·金特里
RedChip Companies
1-407-644-4256
info@redchip.com
SOURCE: RedChip
來源：RedChip
譯文內容由第三人軟體翻譯。